annual FCF:
$10.11B-$58.04M(-0.57%)Summary
- As of today (April 12, 2025), NVO annual free cash flow is $10.11 billion, with the most recent change of -$58.04 million (-0.57%) on December 31, 2024.
- During the last 3 years, NVO annual FCF has risen by +$2.53 billion (+33.40%).
- NVO annual FCF is now -0.57% below its all-time high of $10.16 billion, reached on December 31, 2023.
Performance
NVO Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
-$786.37M-$5.53B(-116.56%)Summary
- As of today (April 12, 2025), NVO quarterly free cash flow is -$786.37 million, with the most recent change of -$5.53 billion (-116.56%) on December 31, 2024.
- Over the past year, NVO quarterly FCF has stayed the same.
- NVO quarterly FCF is now -114.64% below its all-time high of $5.37 billion, reached on June 30, 2024.
Performance
NVO quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$10.11B+$278.41M(+2.83%)Summary
- As of today (April 12, 2025), NVO TTM free cash flow is $10.11 billion, with the most recent change of +$278.41 million (+2.83%) on December 31, 2024.
- Over the past year, NVO TTM FCF has stayed the same.
- NVO TTM FCF is now -14.09% below its all-time high of $11.76 billion, reached on September 30, 2023.
Performance
NVO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
NVO Free cash flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.6% | 0.0% | 0.0% |
| 3 y3 years | +33.4% | +3.8% | +33.4% |
| 5 y5 years | +89.6% | -317.3% | +83.4% |
NVO Free cash flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -0.6% | +33.4% | -114.6% | +26.1% | -14.1% | +37.9% |
| 5 y | 5-year | -0.6% | +120.8% | -114.6% | +62.8% | -14.1% | +120.8% |
| alltime | all time | -0.6% | +9853.3% | -114.6% | +62.8% | -14.1% | +6211.6% |
Novo Nordisk A/S Free cash flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $10.11B(-0.6%) | -$786.37M(-116.6%) | $10.11B(+2.8%) |
| Sep 2024 | - | $4.75B(-11.6%) | $9.83B(+3.4%) |
| Jun 2024 | - | $5.37B(+595.2%) | $9.51B(+29.7%) |
| Mar 2024 | - | $772.71M(-172.6%) | $7.33B(-27.9%) |
| Dec 2023 | $10.16B(+11.8%) | -$1.06B(-124.1%) | $10.16B(-13.6%) |
| Sep 2023 | - | $4.43B(+38.4%) | $11.76B(+21.1%) |
| Jun 2023 | - | $3.20B(-11.4%) | $9.71B(+3.2%) |
| Mar 2023 | - | $3.61B(+574.7%) | $9.41B(+3.5%) |
| Dec 2022 | $9.09B(+20.0%) | $534.67M(-77.5%) | $9.09B(+17.5%) |
| Sep 2022 | - | $2.37B(-18.0%) | $7.74B(-7.8%) |
| Jun 2022 | - | $2.89B(-12.0%) | $8.39B(-9.6%) |
| Mar 2022 | - | $3.29B(-502.4%) | $9.28B(+22.5%) |
| Dec 2021 | $7.58B(+65.5%) | -$817.54M(-127.0%) | $7.58B(+20.7%) |
| Sep 2021 | - | $3.03B(-20.1%) | $6.28B(+17.6%) |
| Jun 2021 | - | $3.79B(+139.5%) | $5.34B(+8.2%) |
| Mar 2021 | - | $1.58B(-174.7%) | $4.93B(+7.8%) |
| Dec 2020 | $4.58B(-14.1%) | -$2.12B(-201.4%) | $4.58B(-35.1%) |
| Sep 2020 | - | $2.09B(-38.3%) | $7.05B(-0.1%) |
| Jun 2020 | - | $3.38B(+176.3%) | $7.06B(+28.1%) |
| Mar 2020 | - | $1.22B(+238.1%) | $5.51B(+3.4%) |
| Dec 2019 | $5.33B(+4.5%) | $361.95M(-82.7%) | $5.33B(-4.5%) |
| Sep 2019 | - | $2.09B(+14.2%) | $5.58B(+17.3%) |
| Jun 2019 | - | $1.83B(+75.7%) | $4.76B(-5.0%) |
| Mar 2019 | - | $1.04B(+69.7%) | $5.01B(-1.7%) |
| Dec 2018 | $5.10B(+3.1%) | $614.42M(-51.7%) | $5.10B(+7.6%) |
| Sep 2018 | - | $1.27B(-39.0%) | $4.74B(-12.0%) |
| Jun 2018 | - | $2.08B(+84.3%) | $5.39B(+17.2%) |
| Mar 2018 | - | $1.13B(+346.4%) | $4.59B(-7.2%) |
| Dec 2017 | $4.95B(-16.8%) | $253.41M(-86.8%) | $4.95B(-16.1%) |
| Sep 2017 | - | $1.92B(+48.3%) | $5.90B(+1.1%) |
| Jun 2017 | - | $1.29B(-13.2%) | $5.84B(-10.3%) |
| Mar 2017 | - | $1.49B(+23.4%) | $6.50B(+9.3%) |
| Dec 2016 | $5.95B(+25.5%) | $1.21B(-34.9%) | $5.95B(+3.1%) |
| Sep 2016 | - | $1.85B(-5.5%) | $5.78B(+4.2%) |
| Jun 2016 | - | $1.96B(+109.2%) | $5.54B(+7.1%) |
| Mar 2016 | - | $936.48M(-9.0%) | $5.18B(+9.2%) |
| Dec 2015 | $4.74B(-2.9%) | $1.03B(-36.5%) | $4.74B(-0.2%) |
| Sep 2015 | - | $1.62B(+1.6%) | $4.75B(-5.8%) |
| Jun 2015 | - | $1.59B(+217.9%) | $5.05B(+5.5%) |
| Mar 2015 | - | $501.18M(-51.8%) | $4.78B(-2.0%) |
| Dec 2014 | $4.88B(+23.0%) | $1.04B(-45.7%) | $4.88B(+4.9%) |
| Sep 2014 | - | $1.91B(+43.9%) | $4.66B(+25.8%) |
| Jun 2014 | - | $1.33B(+121.8%) | $3.70B(+6.4%) |
| Mar 2014 | - | $599.92M(-26.0%) | $3.48B(-12.4%) |
| Dec 2013 | $3.97B(+23.7%) | $810.97M(-15.4%) | $3.97B(+19.9%) |
| Sep 2013 | - | $958.68M(-13.5%) | $3.31B(-4.3%) |
| Jun 2013 | - | $1.11B(+1.5%) | $3.46B(+1.3%) |
| Mar 2013 | - | $1.09B(+619.2%) | $3.42B(+6.4%) |
| Dec 2012 | $3.21B | $151.91M(-86.3%) | $3.21B(-8.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | $1.11B(+4.1%) | $3.52B(-5.5%) |
| Jun 2012 | - | $1.06B(+20.1%) | $3.72B(+8.4%) |
| Mar 2012 | - | $886.23M(+93.4%) | $3.43B(+1.8%) |
| Dec 2011 | $3.37B(+19.9%) | $458.26M(-65.1%) | $3.37B(-6.3%) |
| Sep 2011 | - | $1.31B(+69.2%) | $3.60B(+10.9%) |
| Jun 2011 | - | $775.20M(-6.1%) | $3.24B(+7.9%) |
| Mar 2011 | - | $825.61M(+20.7%) | $3.00B(+6.8%) |
| Dec 2010 | $2.81B(+22.0%) | $684.22M(-28.5%) | $2.81B(+11.2%) |
| Sep 2010 | - | $956.43M(+78.1%) | $2.53B(+3.7%) |
| Jun 2010 | - | $536.90M(-15.3%) | $2.44B(+5.7%) |
| Mar 2010 | - | $633.51M(+58.2%) | $2.31B(+0.1%) |
| Dec 2009 | $2.30B(+7.8%) | $400.55M(-53.8%) | $2.30B(-1.8%) |
| Sep 2009 | - | $866.63M(+113.8%) | $2.35B(+12.7%) |
| Jun 2009 | - | $405.26M(-35.9%) | $2.08B(-5.7%) |
| Mar 2009 | - | $631.92M(+42.7%) | $2.21B(+3.3%) |
| Dec 2008 | $2.14B(+53.6%) | $442.86M(-26.4%) | $2.14B(+6.1%) |
| Sep 2008 | - | $602.09M(+13.3%) | $2.01B(+3.1%) |
| Jun 2008 | - | $531.28M(-5.4%) | $1.95B(+23.3%) |
| Mar 2008 | - | $561.83M(+76.1%) | $1.58B(+13.9%) |
| Dec 2007 | $1.39B(+86.8%) | $319.12M(-41.1%) | $1.39B(+48.2%) |
| Sep 2007 | - | $542.22M(+235.6%) | $938.86M(+9.1%) |
| Jun 2007 | - | $161.57M(-56.2%) | $860.33M(-1.4%) |
| Mar 2007 | - | $368.94M(-375.6%) | $872.96M(+17.2%) |
| Dec 2006 | $745.15M(-7.1%) | -$133.87M(-128.9%) | $745.15M(-29.7%) |
| Sep 2006 | - | $463.69M(+166.2%) | $1.06B(+20.2%) |
| Jun 2006 | - | $174.20M(-27.8%) | $881.55M(-5.6%) |
| Mar 2006 | - | $241.13M(+33.8%) | $934.06M(+16.4%) |
| Dec 2005 | $802.34M(+7.0%) | $180.28M(-37.0%) | $802.34M(+3.7%) |
| Sep 2005 | - | $285.93M(+26.1%) | $773.45M(+2.0%) |
| Jun 2005 | - | $226.71M(+107.2%) | $758.34M(+8.5%) |
| Mar 2005 | - | $109.41M(-27.7%) | $699.17M(-6.8%) |
| Dec 2004 | $749.89M(+34.4%) | $151.39M(-44.1%) | $749.89M(+25.3%) |
| Sep 2004 | - | $270.83M(+61.7%) | $598.50M(+82.7%) |
| Jun 2004 | - | $167.54M(+4.6%) | $327.67M(+104.6%) |
| Mar 2004 | - | $160.13M | $160.13M |
| Dec 2003 | $558.07M(+373.0%) | - | - |
| Dec 2002 | $117.99M(+161.1%) | - | - |
| Dec 2001 | $45.18M(-87.4%) | - | - |
| Dec 2000 | $358.91M(+70.1%) | - | - |
| Dec 1999 | $210.99M(+107.1%) | - | - |
| Dec 1998 | $101.86M(+59.2%) | - | - |
| Dec 1997 | $63.97M(-395.0%) | - | - |
| Dec 1996 | -$21.68M(-113.1%) | - | - |
| Dec 1995 | $166.11M(+13.9%) | - | - |
| Dec 1994 | $145.86M(-293.9%) | - | - |
| Dec 1993 | -$75.24M(-27.4%) | - | - |
| Dec 1992 | -$103.62M(+303.6%) | - | - |
| Dec 1991 | -$25.68M(-147.6%) | - | - |
| Dec 1990 | $53.89M | - | - |
FAQ
- What is Novo Nordisk A/S annual free cash flow?
- What is the all time high annual FCF for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual FCF year-on-year change?
- What is Novo Nordisk A/S quarterly free cash flow?
- What is the all time high quarterly FCF for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly FCF year-on-year change?
- What is Novo Nordisk A/S TTM free cash flow?
- What is the all time high TTM FCF for Novo Nordisk A/S?
- What is Novo Nordisk A/S TTM FCF year-on-year change?
What is Novo Nordisk A/S annual free cash flow?
The current annual FCF of NVO is $10.11B
What is the all time high annual FCF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual free cash flow is $10.16B
What is Novo Nordisk A/S annual FCF year-on-year change?
Over the past year, NVO annual free cash flow has changed by -$58.04M (-0.57%)
What is Novo Nordisk A/S quarterly free cash flow?
The current quarterly FCF of NVO is -$786.37M
What is the all time high quarterly FCF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly free cash flow is $5.37B
What is Novo Nordisk A/S quarterly FCF year-on-year change?
Over the past year, NVO quarterly free cash flow has changed by $0.00 (0.00%)
What is Novo Nordisk A/S TTM free cash flow?
The current TTM FCF of NVO is $10.11B
What is the all time high TTM FCF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high TTM free cash flow is $11.76B
What is Novo Nordisk A/S TTM FCF year-on-year change?
Over the past year, NVO TTM free cash flow has changed by $0.00 (0.00%)